These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 24265292

  • 1. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
    Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W, Denzinger S, Bertz S, Hartmann A, Karl A, Knüchel R, Dahl E.
    Carcinogenesis; 2014 Mar; 35(3):727-36. PubMed ID: 24265292
    [Abstract] [Full Text] [Related]

  • 2. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E.
    Oncogene; 2008 Jan 31; 27(6):865-76. PubMed ID: 17653090
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. ITIH5 mediates epigenetic reprogramming of breast cancer cells.
    Rose M, Kloten V, Noetzel E, Gola L, Ehling J, Heide T, Meurer SK, Gaiko-Shcherbak A, Sechi AS, Huth S, Weiskirchen R, Klaas O, Antonopoulos W, Lin Q, Wagner W, Veeck J, Gremse F, Steitz J, Knüchel R, Dahl E.
    Mol Cancer; 2017 Feb 23; 16(1):44. PubMed ID: 28231808
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gene expression analysis combined with functional genomics approach identifies ITIH5 as tumor suppressor gene in cervical carcinogenesis.
    Dittmann J, Ziegfeld A, Jansen L, Gajda M, Kloten V, Dahl E, Runnebaum IB, Dürst M, Backsch C.
    Mol Carcinog; 2017 Jun 23; 56(6):1578-1589. PubMed ID: 28059468
    [Abstract] [Full Text] [Related]

  • 7. OASIS/CREB3L1 is epigenetically silenced in human bladder cancer facilitating tumor cell spreading and migration in vitro.
    Rose M, Schubert C, Dierichs L, Gaisa NT, Heer M, Heidenreich A, Knüchel R, Dahl E.
    Epigenetics; 2014 Dec 23; 9(12):1626-40. PubMed ID: 25625847
    [Abstract] [Full Text] [Related]

  • 8. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.
    Noetzel E, Rose M, Sevinc E, Hilgers RD, Hartmann A, Naami A, Knüchel R, Dahl E.
    Oncogene; 2010 Aug 26; 29(34):4814-25. PubMed ID: 20543860
    [Abstract] [Full Text] [Related]

  • 9. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
    Dötsch MM, Kloten V, Schlensog M, Heide T, Braunschweig T, Veeck J, Petersen I, Knüchel R, Dahl E.
    Epigenetics; 2015 Aug 26; 10(10):903-12. PubMed ID: 26252352
    [Abstract] [Full Text] [Related]

  • 10. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.
    Clin Genitourin Cancer; 2012 Jun 26; 10(2):114-20. PubMed ID: 22382007
    [Abstract] [Full Text] [Related]

  • 11. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
    Duarte-Pereira S, Paiva F, Costa VL, Ramalho-Carvalho J, Savva-Bordalo J, Rodrigues A, Ribeiro FR, Silva VM, Oliveira J, Henrique R, Jerónimo C.
    Eur J Cancer; 2011 May 26; 47(7):1106-14. PubMed ID: 21273058
    [Abstract] [Full Text] [Related]

  • 12. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C, Kim YW, Ha YS, Kim IY, Kim YJ, Yun SJ, Moon SK, Bae SC, Kim WJ.
    J Surg Oncol; 2012 Mar 15; 105(4):425-30. PubMed ID: 22311819
    [Abstract] [Full Text] [Related]

  • 13. ITIH5 induces a shift in TGF-β superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.
    Rose M, Meurer SK, Kloten V, Weiskirchen R, Denecke B, Antonopoulos W, Deckert M, Knüchel R, Dahl E.
    Mol Carcinog; 2018 Feb 15; 57(2):167-181. PubMed ID: 28940371
    [Abstract] [Full Text] [Related]

  • 14. Epigenetic inactivation of ST6GAL1 in human bladder cancer.
    Antony P, Rose M, Heidenreich A, Knüchel R, Gaisa NT, Dahl E.
    BMC Cancer; 2014 Dec 02; 14():901. PubMed ID: 25465919
    [Abstract] [Full Text] [Related]

  • 15. Epigenetic biomarkers in urothelial bladder cancer.
    Kim WJ, Kim YJ.
    Expert Rev Mol Diagn; 2009 Apr 02; 9(3):259-69. PubMed ID: 19379084
    [Abstract] [Full Text] [Related]

  • 16. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R, van Tilborg AA, Kompier LC, Stumpel DJ, Stam RW, Bangma CH, Zwarthoff EC.
    Eur Urol; 2012 Jun 02; 61(6):1245-56. PubMed ID: 22284968
    [Abstract] [Full Text] [Related]

  • 17. Methylation of the RUNX3 promoter as a potential prognostic marker for bladder tumor.
    Kim EJ, Kim YJ, Jeong P, Ha YS, Bae SC, Kim WJ.
    J Urol; 2008 Sep 02; 180(3):1141-5. PubMed ID: 18639281
    [Abstract] [Full Text] [Related]

  • 18. DBC2 gene is silenced by promoter methylation in bladder cancer.
    Shi Y, Chen JY, Yang J, Li B, Chen ZH, Xiao CG.
    Urol Oncol; 2008 Sep 02; 26(5):465-9. PubMed ID: 18640857
    [Abstract] [Full Text] [Related]

  • 19. Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.
    Chen PC, Yu HJ, Chang YH, Pan CC.
    J Clin Pathol; 2013 Feb 02; 66(2):113-9. PubMed ID: 23087329
    [Abstract] [Full Text] [Related]

  • 20. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ, Lee YS, Kim YJ, Kim MJ, Ha YS, Jeong P, Lee OJ, Kim WJ.
    Urology; 2010 Jun 02; 75(6):1516.e9-13. PubMed ID: 19913893
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.